Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western countries, with a median survival of 6 months and an extremely low percentage of long-term surviving patients. KRAS mutations are known to be a driver event of PDAC 1 , but targeting mutant KRAS has proved challenging 2 . Targeting oncogene-driven signalling pathways is a clinically validated approach for several devastating diseases 3, 4 . Still, despite marked tumour shrinkage, the frequency of relapse indicates that a fraction of tumour cells survives shut down of oncogenic signalling 5, 6 . Here we explore the role of mutant KRAS in PDAC maintenance using a recently developed inducible mouse model of mutated Kras 1 (Kras G12D , herein KRas) in a p53 LoxP/WT background. We demonstrate that a subpopulation of dormant tumour cells surviving oncogene ablation (surviving cells) and responsible for tumour relapse has features of cancer stem cells and relies on oxidative phosphorylation for survival. Transcriptomic and metabolic analyses of surviving cells reveal prominent expression of genes governing mitochondrial function, autophagy and lysosome activity, as well as a strong reliance on mitochondrial respiration and a decreased dependence on glycolysis for cellular energetics. Accordingly, surviving cells show high sensitivity to oxidative phosphorylation inhibitors, which can inhibit tumour recurrence. Our integrated analyses illuminate a therapeutic strategy of combined targeting of the KRAS pathway and mitochondrial respiration to manage pancreatic cancer.
Using our tetracycline-inducible KRas allele 1 , we controlled the expression of KRas in a temporal and pancreas-specific manner. Upon doxycycline withdrawal, we observed regression of pancreatic tumours within 2-3 weeks followed by relapse after 4-5 months, suggesting that a fraction of tumour cells survived oncogene ablation. To investigate the impact of KRas ablation in detail, we transplanted cells from primary tumours subcutaneously into recipient mice fed with doxycycline. When tumours reached a diameter of 1 cm, doxycycline was withdrawn and the lesions rapidly and apparently completely regressed ( Fig. 1a and Extended Data Fig. 1a) . However, analysis of residual scars detected epithelial remnants embedded in fibrotic tissue ( Fig. 1b and Extended Data Fig. 1b, c) . This phenotype was confirmed in vitro using a three-dimensional culture system in which cells from primary lesions were grown as spheres in semisolid medium. After doxycycline withdrawal (Extended Data Fig. 1d , e), tumour spheres underwent regression due to apoptosis (Extended Data Fig. 1f ), and only a small population of dormant cells survived (Extended Data Fig. 1d, g ). Notably, upon KRas re-activation, surviving cells (SCs) massively re-entered the cell cycle both in vitro and in vivo ( Fig. 1c and Extended Data Fig. 1g, h ) and rapidly reconstituted spheres and tumours, suggesting that subpopulations of cells differently addicted to KRas coexist in pancreatic tumours.
To assess the tumorigenic potential of SCs, we isolated KRas-expressing cells and SCs from tumour spheres (ex vitro) and tumours (ex vivo) and transplanted them in limiting dilution into recipient mice. Surprisingly, SCs were highly enriched in tumour-initiating cells (TICs). Virtually all SCs ex vitro initiated tumours in mice (TIC frequency ?1:5 versus 1:31 in KRas-expressing cells; P , 0.001) ( Fig. 1d and Extended Data Fig. 2a ), and TIC frequency was similarly enriched in SCs ex vivo (1:10 versus 1:100 in KRas-expressing cells) ( Fig. 1d and Extended Data Fig. 2b ). Then, to assess whether pharmacological ablation of oncogenic pathways could mimic the genetic suppression of KRas, we treated tumour spheres derived from a KRas constitutive mouse model 7 with a combination of Mek1 (AZD8330) and dual PI3K/mTOR (BEZ235) inhibitors (Extended Data Fig. 2c ). The treatment resulted in an enrichment of tumorigenic cells (TIC frequency 1:7 versus 1:47 for treated versus non-treated cells, respectively) ( Fig. 1d and Extended Data Fig. 2d ). Collectively, our data demonstrate that PDAC tumours are heterogeneous, and that a population of spherogenic and tumorigenic cells survives genetic and pharmacological ablation of oncogenic pathways.
To exclude the possibility that SCs represent a more aggressive subclone of tumour cells, we performed exome sequencing of tumour cells during cycles of KRas activation-inactivation-reactivation (ON-OFF-ON cycles) and evaluated changes in the allelic frequency of single nucleotide variants (SNVs), a hallmark of clonal selection. Mutational profiles did not show any significant modification in allelic frequencies before versus after ON-OFF-ON cycles ( Fig. 1e and Extended Data Fig. 2e ), demonstrating that tumours after KRas reactivation are genetically identical to their primary counterparts. While these data formally exclude genetic clonal selection among SCs, epigenetically driven clonal selection of a more aggressive subclone remains possible.
To characterize SCs further, we examined the expression of markers used to isolate cancer stem cells in human tumours [8] [9] [10] . We found that different subpopulations of tumour cells were differentially sensitive to KRas ablation; specifically, only CD133
1 CD44 high cells avoided undergoing massive apoptosis ( Fig. 1f and Extended Data Fig. 1i ). Consequently, tumour remnants in vivo are strongly positive for stem cell markers (Fig. 1g, h and Extended Data Fig. 2f, g ). Together, the tumorigenicity and immunophenotypic similarity between SCs and previously identified human pancreatic cancer stem cells [8] [9] [10] suggests that SCs may possess cancer stem cell characteristics.
We next performed a transcriptomic analysis of cells isolated from tumour spheres. Gene set enrichment analysis (GSEA) revealed significant enrichment of genes involved in several metabolic pathways (for example, mitochondrial electron transport chain (ETC), lysosome activity, autophagy, mitochondrial and peroxisomal b-oxidation) ( Fig. 1i and Extended Data Fig. 3a-e) , which suggested that SCs might have increased mitochondrial activity. Indeed, Ppargc1a (PGC1a), a key regulator of mitochondrial biogenesis 11 , was increased at the messenger RNA and protein levels in SCs (Fig. 2a and Extended Data Fig. 4a ), and we detected PGC1a accumulation in the nuclei of SCs in vivo (Fig. 2c) . Furthermore, SCs from tumour spheres stained intensely for MitoTracker Green, a marker of mitochondrial mass (Extended Data Fig. 4b ). These data were corroborated by increased expression of the mitochondrial marker VDAC1 in SCs in vitro and in vivo (Fig. 2b, d) .
We functionally validated our findings by measuring respiratory capacity. SCs had a fourfold increase in oxygen consumption rate (OCR) compared with KRas-expressing cells (118 versus 33 pmol min 21 , respectively; P 5 0.001) (Fig. 2e) . Likewise, both in vivo and in vitro, mitochondria of SCs that were either genetically or pharmacologically selected were more hyperpolarized ( Fig. 2f and Extended Data Fig. 4c-f ) and generated more reactive oxygen species (ROS) (Extended Data Fig. 4g, h ), indicating a more active ETC. We also detected morphological differences in mitochondria using transmission electron microscopy (TEM) (Fig. 2g) . Because transmembrane mitochondrial potential regulates the mitochondrial permeability transition pore (lower potential 5 lower threshold for pore opening) and because cells positive for stem cell markers in KRasexpressing tumours have hyperpolarized mitochondria (Extended Data  Fig. 4i, j) , the higher mitochondrial potential per se could explain why cells positive for stem cell markers are less prone to KRas ablation-mediated apoptosis. Altogether, our data suggest that altered metabolic and mitochondrial functions are critical features of SCs.
SCs and KRas-expressing cells were next exposed to mitochondrial stressors. Treatment with oligomycin, a Fo-ATPase inhibitor of Complex V, significantly reduced mitochondrial respiration in both populations (Extended Data Fig. 5a ). Conversely, normalization to basal respiration revealed different effects of the uncoupler carbonyl cyanide-ptrifluoromethoxyphenylhydrazone (FCCP) (Extended Data Fig. 5b) , indicating that the mitochondria of SCs function near their maximal rate and have minimal spare respiratory capacity. Despite similar overall responses to Complex V inhibition, ATP levels of SCs were dramatically reduced upon oligomycin treatment compared to KRas-expressing cells (Fig. 2h) , suggesting a deficit in energy compensatory mechanisms. Indeed, KRas-expressing cells exposed to oligomycin strongly upregulated their extracellular acidification rate (ECAR) and lactate production, a compensation that did not occur in SCs (Fig. 2i and Extended Data Fig. 5c , e), confirming that SCs failed to increase glycolysis after oxidative phosphorylation (OXPHOS) inhibition in a manner sufficient to rescue the defects in ATP production.
To assess comprehensively differences in metabolism, we performed a metabolomic analysis using a liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS)-based platform 1, 12 , revealing that several metabolic pathways were deregulated in SCs (Extended Data Fig. 5d ). Consistent with the above findings, glycolytic intermediates downstream of phospho-fructose kinase (PFK) were significantly less abundant in SCs versus KRas-expressing cells (Fig. 2j) . The impaired glycolysis of SCs was independently validated by measuring glucose 
LETTER RESEARCH
uptake and lactate production in vitro (Fig. 2k, l and Extended Data Fig. 6a ) and in vivo (Extended Data Fig. 6b ). The ratio between lactate and glucose in spent media supports this difference even more strongly (concentration of lactate/concentration of glucose: KRas-expressing cells, 16.9; SCs, 0.9). Importantly, SCs surviving pharmacological ablation of KRas showed a similar phenotype (Extended Data Fig. 6c, d) .
We also detected a decreased abundance of metabolic intermediates specific to the tricarboxylic acid (TCA) cycle in SCs (Extended Data Fig. 5f ). We used carbon-13-labelled primary metabolic substrates to trace their contribution to central carbon metabolism. After 36 h labelling, SCs relied less on glucose and glutamine and more on pyruvate and palmitate to generate TCA cycle intermediates and branching metabolites ( Fig. 2m and Extended Data Fig. 7e-h ). This is consistent with reports describing the mutant KRas-mediated activation of anabolic glucose and glutamine metabolism in PDAC 1, [13] [14] [15] . It is also worth noting that SCs had lower levels of high-energy metabolites (Extended Data Fig. 5g ) (compatible with less anabolic, dormant cells) and increased total glutathione (Extended Data Figs 5g and 8h). Importantly, any effect of cell cycle fluctuations on metabolic processes was excluded by our experimental design, as comparisons were made between quiescent SCs and quiescent fully formed KRas-expressing spheres (Extended Data Fig. 1g ). In fact, we demonstrated that sphere formation is a dynamic and regulated process in which tumour cells expressing KRas exit the cell cycle when tumour spheres are fully formed. Thus, observed metabolic alterations can appropriately be attributed to an autonomous metabolic program.
The lower energy levels and a lack of energetic compensatory mechanisms in response to mitochondrial stressors in SCs suggested that treatment with OXPHOS inhibitors might impact their survival. As expected, even a short, 24 h exposure to oligomycin completely abrogated the ability of SCs to reform tumour spheres upon KRas re-expression, whereas KRas-expressing cells were unaffected ( Fig. 3a and Extended Data Fig. 8a ). Similar effects were observed with other OXPHOS inhibitors, although with less dramatic effects relative to Complex V inhibitors (Extended Data Fig. 8b ). To determine whether OXPHOS inhibition synergized with KRas ablation in vivo, we induced tumour regression for 2 weeks via doxycycline withdrawal, treated mice with oligomycin (0.5 mg kg 21 daily, intraperitoneal (i.p.)) or vehicle, and subsequently re-induced KRas and tumour relapse (Extended Data Fig. 8c-e) . While mice treated with vehicle relapsed immediately (median survival 15 days, maximal survival 19 days), 25% of oligomycin-treated mice survived .60 days (P , 0.0001) ( Fig. 3b and Extended Data Fig. 8f ). Oligomycin treatment also strongly abrogated the spherogenic potential of SCs treated with AZD8330 plus BEZ235 independently of their p53 status (Fig. 3c) . Because OXPHOS inhibitors induce ROS 16 and SCs have elevated basal mitochondrial ROS levels (Extended Data Fig. 4g and Extended Data Fig. 8g ), we excluded the possibility that the observed synthetic lethality of oligomycin was caused by oxidative stress (Extended Data Fig. 8h-k) .
To explore the therapeutic potential of inhibiting OXPHOS in human tumours, we derived spheres from early passage patient-derived xenografts 17 . Similar to the mouse model, combination treatment with AZD8330 and BEZ235 for 1 week strongly decreased sphere formation (Extended Data Fig. 9a-c) , sparing cells endowed with spherogenic potential, increased mitochondrial potential (Extended Data Fig. 9d ) and, most importantly, unable to upregulate ECAR in response to OXPHOS inhibition (Fig. 3d) . As with mouse cells, short exposure of human SCs to oligomycin No. ) and TUFM (a GTPase that delivers aminoacylated transfer RNAs to mitochondrial ribosomes 19 ) decreased the spherogenic potential of human cells surviving combined AZD8330 plus BEZ235 treatment (Extended Data Fig. 9e-h ). Altogether, these data highlight mitochondrial respiration as an attractive, druggable target that may effectively eradicate SCs in PDAC.
The low energy state of SCs suggested that these cells may be experiencing metabolic stress. We thus measured AMPK phosphorylation at Thr 172, an established indicator of metabolic stress. Surprisingly, AMPK phosphorylation was lower in SCs versus KRas-expressing cells (Fig. 4a) ; however, marked induction of AMPK phosphorylation was observed specifically in SCs upon oligomicyn treatment, stressing again the importance of ETC activity for their energy production ( Fig. 4b and Extended Data Fig. 9i ).
To elucidate further the metabolic mechanisms active in SCs, we investigated other targets identified by transcriptomic analysis, including autophagy and b-oxidation. Autophagy and lysosome activity, two of the most activated pathways on the basis of GSEA (Fig. 1i) , have an important 
role in the metabolism of SCs. The autophagic marker microtubuleassociated protein light-chain 3 (LC3) was abundantly expressed in SCs (Fig. 4c) , and lysosomes and autophagosomes at various stages of evolution were abundant (Extended Data Fig. 10a) . To investigate the activation of autophagic flux, we transduced KRas-expressing tumour spheres with LC3-green fluorescent protein (GFP) fusion protein. Cells stably expressing LC3-GFP were maintained in the presence or absence of doxycycline and subsequently analysed by flow cytometry. As shown in Fig. 4d , SCs had a dramatically reduced GFP signal (80%) compared with KRas-expressing cells, indicating that GFP was quenched upon autolysosome formation, as also confirmed by the treatment with bafilomycin, a vacuolar H 1 -ATPase inhibitor (Fig. 4d) . Upon TEM analysis, we observed increased content of cytoplasmic lipid droplets in SCs (Extended Data Fig. 10b ) that we quantified with neutral lipid-specific dyes (Fig. 4e) . Importantly, and unique to SCs, we observed unambiguous evidence of microlipophagy 20 -the fusion of lipid droplets with autophagosomes (Fig. 4f )-which we confirmed by demonstrating strong co-localization of lipid droplets and lysosomes upon staining in SCs (Fig. 4g) . Consistent with observations that SCs catabolize more endogenous protein and fatty acid, tracing metabolic experiments illustrate that more carbon in central metabolism is unaccounted for from labelled substrates in SCs versus KRas-expressing cells (Extended Data Fig. 7e-h ). To determine whether autophagy and microlipophagy may represent a strategy for SCs to maintain their energetic balance 21, 22 , we explored their contribution in maintaining mitochondrial activity by measuring OCR in cells pre-treated with autophagic and b-oxidation inhibitors. Neither inhibitor affected OCR in KRas-expressing cells, whereas treatment with either bafilomycin or etomoxir both markedly reduced OCR in SCs (85% and 35%, respectively) (Fig. 4h) . Importantly, both inhibitors also induced metabolic stress specifically in SCs (Extended Data Fig. 9j, k) and dramatically affected both their spherogenic potential (decrease of .90% and 39%, respectively; P # 0.01) (Fig. 4i) and survival (Extended Data Fig. 9l ). We therefore conclude that autophagy and microlipophagy are as critical as ETC activity for the survival of SCs.
We isolated and characterized tumour cells surviving the genetic and pharmacological ablation of oncogenic pathways, demonstrating that they have features of TICs and a distinct metabolic profile. Unlike highly glycolytic tumour cells, which are dependent on lactate production to regenerate NAD 1 to support continued glycolysis for their anabolic metabolism (Warburg effect), SCs are less glycolytic and more dependent on mitochondrial respiration. Their dependence on OXPHOS for energy production is consistent with recent reports showing that both normal and leukaemic stem cells rely on mitochondrial respiration 19, [23] [24] [25] . Importantly, the strong dependence of ETC activity of SCs on autophagic and catabolic processes makes them more resistant to nutrient deprivation and environmental stressors. However, their inability to increase compensatory fluxes (namely, glycolysis) following OXPHOS inhibition confers extreme sensitivity to inhibition of mitochondrial function, which dramatically impacts their spherogenic and tumorigenic potential. Our findings hold important implications for tumour treatment, paving the way for targeting OXPHOS in association with oncogenic pathway inhibitors to eradicate SCs and prevent tumour relapse in pancreatic cancer.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
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LoxP/WT , p48-Cre mouse model was generated as described 1 . After weaning, mice were fed doxycycline (2 g l In vitro treatments. For drug treatments, KRas-expressing spheres or surviving tumour cells after 8 days of doxycycline withdrawal were collected, washed, digested with trypsin and repeatedly counted (Countless, Invitrogen). Similar procedures were used for spheres derived from human tumours and from the KRas constitutive mouse model except that surviving cells were selected by treating tumour spheres with AZD8330 (10 nM) and BEZ235 (100 nM) for 1 week. Equal numbers of live KRas-expressing cells and surviving tumour cells (AZD8330 plus BEZ235 treated cells for the constitutive KRas and human tumours) were treated with oligomycin (200 nM for 24 h), venturicidin (500 nM for 24 h), DCCD (1 mM for 24 h), bafilomycin (50 nM for 48 h) or etomoxir (100 mM for 48 h). For OCR measurement and western-blot experiments, cells were treated with bafilomycin and etomoxir for 24 and 6 h, respectively. To test the effects of ROS on spherogenic potential, cells were treated with buthionine-sulphoximine (100 mM) to deplete GSH or pre-treated with a-tocopherol (100 mM), N-acetylcysteine (1 mM) or Mn-tetrakis (50 mM) before oligomycin treatment. After drug wash out, treated cells were re-plated for 7 days (on doxycycline when using the KRas-inducible system). The number of tumour spheres (spherogenic potential) was quantified using ImageXpress Velos Laser Scanning Cytometer (Molecular Devices) upon calcein staining (Molecular Probes). , i.p.) at the time of transplantation and then fed with doxycycline in drinking water. Tumourinitiating cell (TIC) frequencies were determined by Poisson statistical analysis using L-Calc software (StemCell Technologies). For BrdU incorporation experiments, mice were injected i.p. with 1 mg of BrdU 3 times (every 8 h) after 24 h or 48 h of KRas reactivation before being killed. For in vivo oligomycin treatment, mice were transplanted with tumour cells and fed with doxycycline in drinking water (1Dox) until tumours reached 1 cm in diameter. At that time, doxycycline was withdrawn (2Dox) and, after 2 weeks, when tumours were almost completely regressed, mice were injected with oligomycin (0.5 mg kg 21 , i.p.; Sigma) or vehicle, 5 days a week, for 2 weeks. After treatment, doxycycline was added back to drinking water and mice were monitored for tumour relapse. Genetically identical and age matched recipient mice were used for transplantation experiments and were randomly allocated for treatment with oligomycin upon tumour regression. Experimenters were not blinded to the experimental groups in evaluating treatment outcome.
For pharmacological inhibition of KRas pathways using small molecule inhibitors, mice bearing tumours derived from the KRas constitutive system were treated with a combination of AZD6244 and BEZ235 (100 mg kg 21 and 40 mg kg 21 respectively, per oral gavage daily) for at least 7 days. Tumour volume was calculated using the formula: V 5 l 2 3 L/2 (where l is length and L is width). All manipulations were performed under IACUC-approved protocols. Isolation of tumour cells. To isolate pure populations of tumour cells from transplanted tumours, we took advantage of dim-high ubiquitous expression of CD44 in pancreatic tumour cells (Extended Data Fig. 2f ). Single-cell suspensions of digested tumours were stained with anti-CD44 biotinylated antibody (eBioscience, IM7). Positive cells were then purified using Easy Sep Biotin Selection Kit (StemCell Technologies) according to manufacturer's instructions. Counterstaining of isolated cells with anti-CD45 and CD31 antibodies and fluorochrome-conjugated streptavidin were used to check the purity by flowcytometry. shRNA expression and gene downregulation. shRNAs against TFAM (TRCN00 00016093; TRCN0000016095) and TUFM (TRCN0000280863; TRCN0000280864) (Sigma) were cloned in a Tet-inducible pLKO vector provided by the Institute for Applied Cancer Science at MDACC (for sequences see also earlier). Human tumour spheres were transduced with viral particles and selected with puromycin. Upon selection, tumour spheres were treated or not with a combination of Mek/Pi3K inhibitors (10 nM AZD83330 plus 100 nM BEZ235) for 1 week. On the second day after beginning the combination drug treatment, doxycycline was added to the culture to induce shRNA expression and was maintained for 5 days. Then tumour cells were collected, washed, and replated to evaluate their spherogenic potential. Downregulation of the target was evaluated by western blot at 72 h after shRNA induction. Flow cytometry and cell sorting. Single cells isolated from tumours or spheres were stained with primary antibodies after blocking with 10% BSA and 5% rat serum. Aldefluor (StemCell Technologies) and annexin V (eBioscience) staining were performed according to the manufacturer's instructions. To study the cell cycle of tumour spheres, BrdU Flow Kit (BD Pharmingen) was used according to datasheet specifications. Mitochondrial potential in vitro was measured using MitoProbe DilC 1 (5) Assay Kit for Flow Cytometry (Molecular Probes) according to specifications, and CCCP treatment was used for controls. In vivo mitochondrial potential was evaluated according to Zheng et al.
27
. Briefly, mice bearing KRas-expressing or regressed tumours (inducible model or pharmacologically treated with AZD6244 plus BEZ235) were injected with 25 nmol kg 21 of TMRE (Molecular Probes) as a tail vein bolus. After 1 h, mice were killed and tumours explanted, digested (as described earlier, adding 10% FBS to the digestion mix) and stained for CD44. Samples were kept on ice and immediately acquired gating CD44-positive DAPI-negative cells. The same approach, timeline and staining were used to evaluate glucose uptake in vivo, injecting 25 mmol kg 21 2NBDG (Molecular Probes) as a tail vein bolus according to Ytoh et al.
28
. For in vitro experiments, 2NBDG was used at a concentration of 10 mM in complete stem cell medium containing 2 mM glucose 28 . Cells were incubated for 6 h then washed and analysed by flow cytometry. MitoTracker Green and Deep Red (Molecular Probes) were used to measure mitochondrial mass. ROS were evaluated using MitoSOX and CellROX (Molecular Probes) and induced by 4-hydroxynonenal treatment (10 mM) for positive controls. LipidTox deep red (Molecular Probes) was used for quantifying lipid droplet content. All staining procedures were performed according to the manufacturer's protocols. DAPI (Invitrogen) was used to stain DNA content or to exclude dead cells depending on the experiment. For measuring autophagic flux, KRas-expressing cells were transduced with pBABEPuro GFP-LC3 (ref. 26) and, upon selection, doxycycline was withdrawn for 8 days. Mean of fluorescence of surviving and matched KRas-expressing cells was quantified and surviving tumour cells treated for 24 h with bafilomycin (50 nM) were used as a control. Gating strategies to exclude doublets and dead cells (DAPI) were always employed. After staining, LETTER RESEARCH samples were acquired using a BD FACSCantoII flow cytometer or sorted using BD Influx cell sorter. Data were analysed by BD FACSDiva or FlowJo (Tree Star). Immunohistochemistry and immunofluorescence. Tumour samples were fixed in 4% formaldehyde for 2 to 4 h on ice, moved in 70% ethanol for 12 h, and then embedded in paraffin (Leica ASP300S). After cutting (Leica RM2235), baking and deparaffinization, slides were treated with Citra-Plus Solution (BioGenex) according to specifications. For immunohistochemistry (IHC) staining, endogenous peroxidases were inactivated by 3% hydrogen peroxide. Non-specific signals were blocked using 3% BSA, 10% goat serum and 0.1% Triton. Tumour samples were stained with primary antibodies. For BrdU detection, samples were digested on slides for 1 h at 37 uC with DNase I (300 mg ml 21 ) before staining. For IHC, ImmPress and ImmPress-AP (Vector Lab) were used as secondary antibodies and Nova RED, Vector BLUE and DAB were used for detection (Vector Lab). Images were captured with a Nikon DS-Fi1 digital camera using a wide-field Nikon EclipseCi microscope. For immunofluorescence, secondary antibodies conjugated with Alexa488 and 555 (Molecular Probes) were used. Images were captured with a Hamamatsu C11440 digital camera, using a wide-field Nikon EclipseNi microscope. LipidTox, Lysotracker, MitoTracker, CellRox and Hoechst 33342 (Molecular Probes) were used on live spheres and cells at the concentrations suggested by manufacturer's protocols and images were acquired using a Nikon high-speed multiphoton confocal microscope A1 R MP. Immunoblotting. Protein lysates were resolved on 5-15% gradient polyacrylamide SDS gels and transferred onto PVDF membranes according to standard procedures. Membranes were incubated with indicated primary antibodies, washed, and probed with HRP-conjugated secondary antibodies. The detection of bands was carried out upon chemiluminescence reaction followed by film exposure. For the Ras pull-down assay, the amount of active Ras was evaluated by detecting the fraction of Ras protein that co-precipitated with RAF kinase. Cell lysates from KRasexpressing cells and cells surviving KRas ablation were co-incubated with RAF-linked agarose beads for 2 h. After incubation, beads were collected, washed and boiled for 5 min in the presence of laemmli loading buffer supplemented with 10% 2-mercapthoethanol and ultimately loaded onto SDS-PAGE gels. The detection of the active fraction of RAS was carried out using standard western blot procedures with anti-Ras antibody. Transmission electron microscopy. TEM was performed at the MDACC High Resolution Electron Microscopy Facility. Samples were fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, for 1 h. After fixation, the samples were washed and treated with 0.1% Milliporefiltered cacodylate buffered tannic acid, post-fixed with 1% buffered osmium tetroxide for 30 min, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were dehydrated in increasing concentrations of ethanol, infiltrated and embedded in LX-112 medium. The samples were polymerized in a 60 uC oven for 2 days. Ultrathin sections were cut in a Leica Ultracut microtome, stained with uranyl acetate and lead citrate in a Leica EM Stainer and examined in a JEM 1010 transmission electron microscope (JEOL) at an accelerating voltage of 80 kV. Digital images were obtained using an AMT Imaging System (Advanced Microscopy Techniques Corp). DNA, RNA, cDNA and qPCR. DNA and RNA were extracted using DNeasy Blood and Tissue Kit (Qiagen) and RNeasy Mini Kit (Qiagen) according to technical specifications. A mix of random hexamers and oligo(dT) were applied for cDNA synthesis using SuperScript III First-Strand-Synthesis System (Invitrogen). For qPCR, 10 ng of DNA or cDNA was amplified with EXPRESS SYBR GreenER qPCR SuperMix (Invitrogen) using a Startagene Mx3005p thermal-cycler. Primers used for mitochondrial and lipid metabolic gene amplification are shown in Extended Data Fig. 10c . b-Actin (F-GACGGCCAGGTCATCACTAATTG, R-AGGAAGGCTG GAAAAGAGCC), 28S (F-TCATCAGACCCCAGAAAAGG, R-GATTCGGCA GGTGAGTTGTT) and b-microglobulin (F-ATTCACCCCACTGAGACTG, R-TGCTATTTCTTTCTGCGTGC) were used as house-keeping genes for normalization. Expression of genes involved in the ETC, mitochondria and autophagy was evaluated using Qiagen commercial arrays: RT2 Profiler PCR Array Mouse Mitochondrial Energy Metabolism, Mouse Mitochondria and Mouse Autophagy. Expression profiling and data analysis. Gene expression profiling was performed at the Dana-Farber Cancer Institute Microarray Core Facility. RNA isolated from KRas-expressing and surviving tumour cells was hybridized on a Gene Chip Mouse Genome 430 2.0 Array (Affymetrix). Raw data (CEL files) were pre-processed using a robust multi-array analysis (RMA) and analysed with GSEA 29 using Signalling Pathways c2.cp.v3.0 and TFT c3.tft.v3.0 symbols gene sets. Exome sequencing. Two independent tumour spheres expressing KRas were collected, digested to single cells, and replated on two plates in the presence of doxycycline (ON Dox, 1KRas) for 1 week. Spheres from one plate were collected and snap frozen for DNA extraction (Reference), while spheres from the other plate were plated OFF doxyclycline (2KRas) for 1 week before re-addition of doxycycline to re-express KRas. After 1 week, reformed spheres were collected and snap frozen for DNA extraction (Re-ON). Genomic DNA was extracted by phenol-chloroform and further purified from contamination on columns (Qiagen). The exonic DNA regions were captured using Nimblegen SeqCap EZ Mouse Exome kit. The DNA sequences recovered were processed through a standard SNP calling pipeline. Reads were aligned using BWA following removal of duplicates, realignment and recalibration (using Broad's Genome Analysis Toolkit or GATK). Further SNPs were called using GATK's Unified Genotyper and annotated using Annovar. For the analysis we considered SNVs which were (1) called in both samples, and (2) had a minimum coverage of 200 in both, providing enough confidence to compare allelic frequencies between the sample pairs. Roughly 12% (40,383/335,076) and 13% (44,182/339,398) of the common SNVs for tumour #2 and tumour #1, respectively, satisfied the coverage threshold of 200. Metabolomics. For metabolomic analyses, surviving and KRas-expressing spheres (grown as described earlier), were collected after 8 days of culture when both KRasexpressing spheres and surviving tumour cells were confirmed to have exited the cell cycle (to avoid the confounding effects of proliferation on metabolism) (Extended Data Fig. 1g ). The day before collection, medium was changed and spheres re-plated in fresh medium. After 24 h, cells were collected by centrifugation, washed three times and samples were then immediately lysed in methanol:water (80:20) at dryice temperature. The quantity of the metabolite fraction analysed was adjusted to the corresponding protein concentration calculated upon processing a parallel sample. Metabolite fractions were processed and analysed by targeted LC-MS/MS via selected reaction monitoring (SRM), as described 1, 12, 14 . Processed data were analysed in Cluster 3.0 and TreeViewer. The analysis was performed on four independent tumours in biological triplicate. Carbon-13 metabolic tracing. Cells were prepared in a manner identical to that for routine metabolomic profiling (see earlier), except that media formulations were adjusted to account for isotopically labelled substrates. Specifically, surviving and KRas-expressing cells were plated in RPMI medium (reconstituted with growth factors) devoid of glucose, glutamine, pyruvate, palmitate and supplemented with one of the four carbon-13-labelled substrates where the remaining substrates were unlabelled (glucose 10 mM, glutamine 2 mM, pyruvate 1 mM and palmitate 75 mM). After 24 h of incubation with labelled substrates, cells were collected and replated again in fresh media supplemented with carbon-13-labelled substrates for another 12 h to minimize the effects of cellular uptake on the concentration of different substrates. After 36 total hours of labelling, samples were collected by centrifugation and immediately lysed in methanol:water (80:20) at dry-ice temperature. As for metabolomics, the quantity of the metabolite fraction analysed was adjusted to the corresponding protein concentration from a sample processed in parallel. The analysis was performed for each of the four substrates on three independent tumours in biological triplicate. Data were collected and processed as above, as described 1, 12, 14 . Oxygen consumption and glycolytic capacity. Tumour spheres and surviving cells were digested to single cells and spun into XF96 Cell Culture Microplates (Seahorse Bioscience) previously treated with Cell-Tak (BD Biosciences) immediately before the experiment. To measure OCR and the response to OXPHOS inhibition, we plated cells in complete stem cell medium (see earlier) prepared with MEBM lacking NaHCO 3 (Lonza) and supplemented with 5 mM pyruvate (Sigma). Oligomycin, FCCP, antimycin and rotenone (XF Cell Mito Stress Test Kit, Seahorse Bioscience) were sequentially injected at a final concentration of 1 mM. To measure ECAR, we plated tumour cells in base assay medium (D5030, Sigma) adjusted to pH 7.4. Glucose (10 mM final concentration, Sigma), oligomycin (1 mM final concentration) and 2-deoxy-glucose (100 mM final concentration) were sequentially injected (XF Glycolysis Stress Test Kit, Seahorse Bioscience). Specifically for the experiment in Extended Data Fig. 5c , ECAR was measured in complete stem cell media to evaluate the glycolytic reserve of tumour cells in a nutrient-rich environment. Oligomycin and 2DG were sequentially injected at a final concentration of 1 mM and 100 mM, respectively. Experiments were run using a XF96 analyser and raw data were normalized to metabolically active cells, evaluated as Hoechst 33342 positive/ propidium iodide negative, by an Operetta High-Content Imaging System (PerkinElmer) immediately after each experiment. Glucose uptake and lactate production. To measure glucose uptake, we used two different approaches: by flow cytometry using the fluorescent glucose analogue 2NBDG (see earlier) and by YSI 2950 Biochemistry Analyzer (YSI Life Sciences). For YSI, the same number of surviving cells and KRas-expressing cells was plated in triplicate in a 96-well plate in 200 ml of complete stem cell medium. After 24 h, the medium was collected and glucose and lactate concentrations were evaluated by YSI analyser, using unconditioned fresh medium as a reference. Lactate production in response to oligomycin treatment (200 nM) was independently measured by Lactate Kit (Trinity Biotech) to directly evaluate the concentration of lactic acid in stem cell medium 6 to 12 h after tumour cell plating. ATP and glutathione assays. ATP production of tumour cells in response to 6 to 12 h of oligomycin treatment (200 nM) was measured using Cell Titer Glo (Promega)
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following the manufacturer's instructions. For glutathione, cells were lysed by sonication in 13 GSH MES buffer (Cayman Chemical) and debris was pelleted by high-speed centrifugation. Samples were deproteinized by adding vol:vol of meta-phosphoric acid (1 mg ml 21 ) followed by centrifugation and pH equilibration by the addition of triethanolamine. Glutathione content was evaluated through an enzymatic recycling method by using a commercially available kit (Cayman Chemical). PHERAStar plus microplate reader (BMG Labtech) was used to measure luminescence and absorbance. Statistical analysis. In vitro and in vivo data are presented as the mean 6 s.d. Statistical analyses were performed using a two-tailed Student's t-test after the evaluation of variance. Results from survival experiments were analysed with a Gehan-BreslowWilcoxon test and expressed as Kaplan-Meier survival curves.
Extended Data Figure 
